KDR and neoplasm: Anlotinib, a multi-targeted tyrosine kinase inhibitor, markedly aids in normalizing tumor vasculature by selectively blocking receptors like VEGFR2/3, PDGFR-β, and FGFR1-4, which consequently boosts local blood flow and improves oxygen partial pressure (19).